Dr. Manji on Lack of Actionable Targets in Patients with Colorectal Cancer

Video

In Partnership With:

Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.

Gulam A. Manji, MD, PhD, director, Medical Oncology and Translational Research for The Pancreas Center, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, discusses the importance of discovering other actionable targets for patients with colorectal cancer (CRC).

The search continues for additional actionable targets in patients with CRC, says Manji. Identifying these mutations could help increase the efficacy of available treatment and improve patient survival.

Other than those with KRAS mutations, there has been little success in finding another target present in a large proportion of patients, he explains. For example, in other cancer types, there are rare diseases where a large proportion of patients who have the NTRK mutation can benefit from treatment. Unfortunately, that is not the case for gastrointestinal malignancies, says Manji.

However, a considerable percentage of mutation-negative gastrointestinal stromal tumors harbor a NTRK translocation, so some efficacy may be seen there, concludes Manji.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute